Liminal BioSciences gets Nasdaq notice on minimum bid price deficiency
Mar. 07, 2022 5:10 PM ETLMNLBy: Jessica Kuruthukulangara, SA News Editor1 Comment
- Liminal BioSciences (NASDAQ:LMNL) received a written notice from the Nasdaq indicating that it is not in compliance with the minimum bid price requirement of $1/share.
- In the event LMNL does not regain compliance by Aug. 31, the company may be eligible for additional time to regain compliance or may face delisting.
- LMNL fully intends to resolve the deficiency and regain compliance with the listing rules.